Insias Email Formats

Pharmaceutical Manufacturing • • 1-10 Employees

Key Contact at Insias

Mart Boonen

Owner

Company overview

Headquarters	XX
NAICS	3254
Employees	1-10

About Insias

INSIAS (In Silico Assessments) is committed to support pharmaceutical and biotech, as well as medical device companies in the qualification of their product related impurities whilst avoiding animal testing, whenever feasible. When no adequate experimental mutagenicity and/or carcinogenicity results are available, a structure-based computational toxicology or (Q)SAR analysis may be used to predict the mutagenic potential of an impurity. (Q)SAR models are also available for other endpoints such as, but not limited to, irritation and sensitization.